Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTI Vaccines ATI Extension in HIV-1
NCT04385875Phase 1Completed
- Start
- Jun 2020
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of DNA.HTI, MVA.HTI and ChAdOx1.HTI in human immunodeficiency virus type 1 infection (HIV-1) (2 arms). Primary endpoints: Percentage of participants with viral remission at Week 72, Percentage of participants with viral control at Week 72 and 4 more. Started Jun 2020; status: completed.
02
Drugs
DNA.HTIMVA.HTIChAdOx1.HTI
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04385875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385875.